Healthcare / BiotechnologyKOSDAQ
$1551.00
-59.00 (-3.66%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-8.0B · quality 63.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$28.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-17.0%
↓Gross Margin
37.5%
↓Debt/Equity
0.35
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-37.3%
FCF CAGR
—
FCF margin
-79.3%
FCF / Net income
0.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $9.40B · net income $-11.64B · FCF $-7.45B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $9.40B | $9.40B | $7.14B | $9.76B | $38.08B |
| Net Income | $-11.64B | $-11.64B | $-6.83B | $-5.51B | $14.60B |
| EBITDA | $-9.35B | $-9.35B | $-4.31B | $-5.51B | $18.88B |
| EPS | -644.00 | -644.00 | -378.00 | -300.00 | 384.50 |
| Gross Margin | 37.5% | 37.5% | 33.2% | 46.3% | 69.2% |
| Operating Margin | -91.9% | -91.9% | -128.4% | -72.6% | 38.7% |
| Net Margin | -123.8% | -123.8% | -95.7% | -56.5% | 38.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.35 | 0.35 | 0.30 | 0.28 | 0.18 |
| Current Ratio | 1.30 | 1.30 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-7.45B | $-7.45B | $-13.62B | $-8.02B | $-8.99B |
| Returns | |||||
| ROE | -17.0% | -17.0% | -8.5% | -6.3% | 15.4% |
| Valuation | |||||
| P/E | — | — | — | — | 12.47 |
| EV/EBITDA | — | — | — | — | 10.15 |
| P/B | 0.41 | 0.41 | 0.49 | 0.80 | 1.92 |
| Growth & Yield | |||||
| Revenue Growth | 31.8% | 31.8% | -26.9% | -74.4% | — |
| EPS Growth | -70.4% | -70.4% | -26.0% | -178.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-31.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-378.00 → -644.00
Residual
-31.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.